Cardiodilatin fragment, process for preparing same and use thereof
June 7, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesInhibition of aldosterone secretion Cardiodilatin, a new peptide hormone and process for its preparation Composition containing cordiodilatin or fragments thereof and methods of obtaining cardiodilatin Method for determining cardiodilatin and fragments thereof and antibodies useful in determination of cardiodilatin and its fragments Cardiodilatin fragment, process for preparing same and use thereof Phosphorylated derivatives of cardiodilatin/ANF peptides Patent #: 5461142 InventorsAssigneeApplicationNo. 480359 filed on 06/07/1995US Classes:530/334, Polymer supported synthesis, e.g., solid phase synthesis, Merrifield synthesis, etc.530/335, Protecting or removing protective groups, e.g., carboxyl group protection, etc.530/338, Solution phase synthesis530/339, Segment condensation, e.g., Ugi condensation, etc.530/344, Separation or purification530/834Urine; urinary systemExaminersPrimary: Russel, Jeffrey E.Attorney, Agent or FirmForeign Patent References
International ClassesC07K 001/02C07K 001/04 C07K 001/06 C07K 001/14 Foreign Application Priority Data1987-03-02 DEAbstractDescribed is a peptide fragment which comprises the amino acid sequence 95-126 of ANF/CDD 1-126 (gamma-hANaP) and is formed in the kidney. The fragment urodilatin (ANF/CDD 95-126) has the following amino acid sequence: ##STR1## wherein R1 and R2 each represent further peptide fragments of ANF/CDD 1-126 (gamma-hANaP). In the amino acid sequence R1 is Thr-Ala-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser and R2 is Asn-Ser-Phe-Arg-Tyr. Further described are processes for the preparation and/or recovery of the new peptide fragment and a medicament containing urodilatin (ANF/CDD 95-126) as well as medical indications of the medicament.Other References
Field of SearchPEPTIDE, PROTEIN OR AMINO ACIDMonocyclic 25 or more peptide repeating units in known peptide chain structure 25 or more amino acid residues in defined sequence Polymer supported synthesis, e.g., solid phase synthesis, Merrifield synthesis, etc. Protecting or removing protective groups, e.g., carboxyl group protection, etc. Solution phase synthesis Segment condensation, e.g., Ugi condensation, etc. Separation or purification Urine; urinary system Atrial or brain natriuretic peptide; related peptides |
| ||||||||||||||
